Recently, Momed Biotech has utilized its MechGen drug discovery platform to precisely identify novel neuroprotective pathway targets from massive datasets and lock in a lead drug molecule for Parkinson’s disease treatment. The molecule demonstrated promising results in preclinical studies, showing potential to rapidly advance into Phase II clinical trials for neurodegenerative indications—highlighting the formidable advantages of AI-aided drug discovery.